Research Article
Effect of Voriconazole on Tacrolimus Blood Concentration in Renal Transplant Recipients after Voriconazole Discontinuation
Table 2
Baseline laboratory test results before and after VRC discontinuation.
| Parameter | Co-VRC | Post-VRC | t/Z | |
| ALB(g/L)a | 36.23 ± 5.12 | 37.88 ± 6.39 | −1.310 | 0.197 | TBIL(µmol/L)b | 9.70 (7.95, 13.40) | 10.00 (8.10, 13.13) | −0.920 | 0.358 | ALT (U/L)b | 20.00 (16.00, 32.25) | 24.50 (17.00, 49.25) | −1.559 | 0.119 | AST (U/L)b | 18.00 (14.00, 28.00) | 20.50 (15.75, 44.25) | −0.961 | 0.337 | CRE (µmol/L)b | 210 (130.05, 383.65) | 180.75 (107.40, 329.35) | −1.797 | 0.072 | CCR (mL/min)b | 32.50 (14.75, 57.25) | 41.00 (19.00, 72.50) | −1.338 | 0.181 | u-hsCRP (mg/L)b | 4.09 (1.93, 10.38) | 4.19 (1.67, 28.77) | −0.845 | 0.398 | HB (g/L)a | 88.65 ± 13.82 | 87.69 ± 15.14 | 0.371 | 0.713 | HCV (%)a | 26.92 ± 4.17 | 26.87 ± 4.60 | −0.053 | 0.958 |
|
|
Albumin (ALB), total bilirubin (TBIL), glutamic aminotransferase (ALT), glutamic oxalacetic aminotransferase (AST), CRE (blood creatinine), CCR (creatinine clearance), C-reactive protein (u-hsCRP), hemoglobin (HB), and erythrocyte specific volume (HCV). athe paired t-tes, mean ± SD; bthe Wilcoxon signed-rank test, median (IQR).
|